Trial Profile
Phase 3 Study of Erlotinib 100mg or 150mg in Treating EGFR Mutated Patients With Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Feb 2015 Planned number of patients changed from 304 to 220 as reported by ClinicalTrials.gov record.
- 20 May 2014 New trial record